Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × bicalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 45 Breast Neoplasms 7 Bulbo-Spinal Atrophy, X-Linked 4 Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 Stage I Prostate Adenocarcinoma 1 Recurrence 1 Paget Disease, Extramammary 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Lower Urinary Tract Symptoms 1 Fallopian Tube Neoplasms 1 Erectile Dysfunction 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1 Adenocarcinoma 1

Interventions

pembrolizumab 21 Gemcitabine 21 Nivolumab 13 Cisplatin 13 atezolizumab 12 avelumab 11 Carboplatin 10 Docetaxel 9 enfortumab vedotin 7 Paclitaxel 7 durvalumab 6 Magnetic Resonance Spectroscopy 6 Ipilimumab 6 pemigatinib 5 Specimen Handling 5 vinflunine 4 toripalimab 4 sacituzumab govitecan 4 cabozantinib 4 Taxes 4 Pemetrexed 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 tislelizumab 2 sapanisertib 2 disitamab vedotin 2 cabazitaxel 2 Trastuzumab 2 Standard of Care 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡